Squarepoint Ops LLC Boosts Position in Passage Bio, Inc. (NASDAQ:PASG)

Squarepoint Ops LLC lifted its position in shares of Passage Bio, Inc. (NASDAQ:PASG) by 129.5% during the 4th quarter, HoldingsChannel reports. The firm owned 64,099 shares of the company’s stock after acquiring an additional 36,172 shares during the period. Squarepoint Ops LLC’s holdings in Passage Bio were worth $36,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its position in shares of Passage Bio by 983.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 54,479 shares of the company’s stock valued at $31,000 after purchasing an additional 49,449 shares in the last quarter. Northern Trust Corp boosted its position in shares of Passage Bio by 55.1% during the fourth quarter. Northern Trust Corp now owns 62,476 shares of the company’s stock valued at $35,000 after purchasing an additional 22,195 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Passage Bio by 537.2% during the fourth quarter. Jane Street Group LLC now owns 78,190 shares of the company’s stock valued at $44,000 after purchasing an additional 65,919 shares in the last quarter. Shay Capital LLC boosted its position in shares of Passage Bio by 144.2% during the fourth quarter. Shay Capital LLC now owns 225,261 shares of the company’s stock valued at $128,000 after purchasing an additional 133,005 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Passage Bio by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 531,565 shares of the company’s stock valued at $302,000 after purchasing an additional 22,049 shares in the last quarter. 53.48% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, major shareholder Orbimed Advisors Llc sold 78,049 shares of the company’s stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $0.34, for a total value of $26,536.66. Following the completion of the transaction, the insider now owns 6,807,523 shares of the company’s stock, valued at $2,314,557.82. This represents a 1.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 233,660 shares of company stock worth $77,723 over the last quarter. 5.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, Chardan Capital dropped their price target on Passage Bio from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.

Passage Bio Stock Performance

Passage Bio stock opened at $0.48 on Wednesday. The stock has a market cap of $29.80 million, a PE ratio of -0.41 and a beta of 1.71. Passage Bio, Inc. has a one year low of $0.26 and a one year high of $1.33. The stock has a fifty day moving average of $0.36 and a 200 day moving average of $0.51.

Passage Bio (NASDAQ:PASG) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). As a group, sell-side analysts predict that Passage Bio, Inc. will post -1.03 EPS for the current fiscal year.

Passage Bio Company Profile

Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.